Safety of bevacizumab and olaparib as frontline maintenance therapy in advanced ovarian cancer: expert review for clinical practice
Olaparib, a poly(ADP-ribose) polymerase inhibitor, in combination with the antiangiogenic agent bevacizumab, is approved as maintenance therapy for patients with newly diagnosed stage III or IV epithelial ovarian cancer who have homologous recombination deficient tumors with a deleterious or suspect...
Збережено в:
| Автори: | , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Frontiers Media S.A.
2024-01-01
|
| Серія: | Frontiers in Oncology |
| Предмети: | |
| Онлайн доступ: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1304303/full |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|